Novavax company claims readiness of new Covid-19 vaccine

Source : 112 Ukraine

The efficacy of the vaccine is almost 100%
12:19, 29 January 2021

Open source

The third and final stage of trials of the Novavax vaccine from coronavirus is finished, as American vaccine development company Novavax reported.

“Candidate NVX -CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK),” the message said.

Related: Patient in Lithuania gets five doses of Covid-19 vaccine

The medicine was also tested on the ‘British’ strain of coronavirus. On the basis of the tests, it is established that Novavax vaccine’s efficacy is 95.6% against the main strain and 85.6% against the new mutation. Over 15,000 participants at the age of 18 up to 84 were involved in the trial, including 27% of people over the age of 65.

Earlier, Novavax reported the positive results of the early testing of its vaccine from Covid-19 that showed that it might cause the immune response and it is safe in general.

Related: 367,000 Ukrainians to get vaccinated against Covid-19 during first stage, - official

As we reported, the European Medicines Agency (EMA) has approved AstraZeneca Covid-19 vaccine for use in the EU. The final decision on the use of this vaccine in the EU member states must be made by the European Commission. 

Watch review of Year 2020 here:


Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more